Is Anavex Life Sciences Corp. (AVXL) a Buy, Sell, or Hold?
Anavex Life Sciences Corp.
NASDAQ:AVXL
$2.5 USD
$0.07 (2.88%)
- Volume
- 715.84K
- Average Volume
- 1.19M
- Market Capitalization
- $231.68M
- P/E Ratio
- -5.39
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $13.99
- Year Low
- $2.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.87
| Source | Headline |
|---|---|
|
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company's inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026. globenewswire.com - 2026-05-22 08:00:00 |
|
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company's former Senior Vice President of Clinical Development and current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of President and Chief Executive Officer Christopher Missling, PhD, MS, MBA, from the Company on April 30, 2026, and a request for his resignation from the Board of Directors. globenewswire.com - 2026-05-06 07:00:00 |
